New Zealand markets closed

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.6900+0.0300 (+1.81%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 7.36M
Enterprise value 2.99M
Trailing P/E 0.50
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)25.08
Price/book (mrq)3.76
Enterprise value/revenue 18.19
Enterprise value/EBITDA -0.24

Trading information

Stock price history

Beta (5Y monthly) 0.56
52-week change 3-57.64%
S&P500 52-week change 322.36%
52-week high 35.0900
52-week low 30.9700
50-day moving average 31.8350
200-day moving average 31.8734

Share statistics

Avg vol (3-month) 329.71k
Avg vol (10-day) 332.56k
Shares outstanding 54.35M
Implied shares outstanding 64.35M
Float 84.21M
% held by insiders 11.45%
% held by institutions 13.27%
Shares short (15 Apr 2024) 446.5k
Short ratio (15 Apr 2024) 41.93
Short % of float (15 Apr 2024) 41.07%
Short % of shares outstanding (15 Apr 2024) 41.07%
Shares short (prior month 15 Mar 2024) 432.23k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 306 Aug 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 301 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -271.04%
Operating margin (ttm)-293.98%

Management effectiveness

Return on assets (ttm)-47.23%
Return on equity (ttm)-522.50%

Income statement

Revenue (ttm)4.91M
Revenue per share (ttm)1.56
Quarterly revenue growth (yoy)769.50%
Gross profit (ttm)N/A
EBITDA -12.69M
Net income avi to common (ttm)-13.32M
Diluted EPS (ttm)-4.2400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.55M
Total cash per share (mrq)2
Total debt (mrq)4.18M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.92
Book value per share (mrq)-0.30

Cash flow statement

Operating cash flow (ttm)-12.85M
Levered free cash flow (ttm)-8.31M